The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate.

Cite this paper

@article{Schuster2003TheEO, title={The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate.}, author={Christine Schuster and Karin Forster and Henning Dierks and Annika Elsasser and Gerhard Behre and Nicola Simon and Susanne Danhauser-Riedl and Michael J Hallek and Markus Warmuth}, journal={Blood}, year={2003}, volume={101 2}, pages={655-63} }